DiaMedica Therapeutics Inc (NASDAQ:DMAC) — Market Cap & Net Worth
Market Cap & Net Worth: DiaMedica Therapeutics Inc (DMAC)
DiaMedica Therapeutics Inc (NASDAQ:DMAC) has a market capitalization of $340.54 Million ($340.54 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14301 globally and #3410 in its home market, demonstrating a 1.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DiaMedica Therapeutics Inc's stock price $6.63 by its total outstanding shares 53883345 (53.88 Million). Also see DiaMedica Therapeutics Inc total assets for a full breakdown of the balance sheet.
DiaMedica Therapeutics Inc Market Cap History: 2015 to 2026
DiaMedica Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $102.38 Million to $357.25 Million (13.00% CAGR). Also see cash flow conversion of DiaMedica Therapeutics Inc for how efficiently the company converts equity into cash flow.
Index Memberships
DiaMedica Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #388 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1395 of 3165 |
Weight: DiaMedica Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DiaMedica Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DiaMedica Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check DMAC share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
313.60x
DiaMedica Therapeutics Inc's market cap is 313.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $156.80 Million | $500.00K | -$5.73 Million | 313.60x | N/A |
Competitor Companies of DMAC by Market Capitalization
Companies near DiaMedica Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review how tangible is DiaMedica Therapeutics Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to DiaMedica Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
DiaMedica Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, DiaMedica Therapeutics Inc's market cap moved from $102.38 Million to $ 357.25 Million, with a yearly change of 13.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $357.25 Million | -16.71% |
| 2025 | $428.91 Million | +46.59% |
| 2024 | $292.59 Million | +91.20% |
| 2023 | $153.03 Million | +79.74% |
| 2022 | $85.14 Million | -57.64% |
| 2021 | $200.98 Million | -63.21% |
| 2020 | $546.38 Million | +109.07% |
| 2019 | $261.33 Million | +66.67% |
| 2018 | $156.80 Million | -41.80% |
| 2017 | $269.42 Million | +127.69% |
| 2016 | $118.33 Million | +15.58% |
| 2015 | $102.38 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of DiaMedica Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $340.54 Million USD |
| MoneyControl | $340.54 Million USD |
| MarketWatch | $340.54 Million USD |
| marketcap.company | $340.54 Million USD |
| Reuters | $340.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more